Compositions and methods for optimizing exercise recovery

• US 20070042972A1
• Filed: 05/23/2006
• Published: 02/22/2007
• Est. Priority Date: 05/24/2005
• Status: Abandoned Application

• Current Assignee: Rutgers University
• Original Assignee: Rutgers University
• Inventors: Liburt, Nettie, Streltsova, Jennifer, Rosen, Sharon, Rosen, Robert, McKeever, Kenneth, Franke, William
• Application Number:
  US11/439,718
• Publication Number:
  US 20070042972A1
• Time in Patent Office: Days
• US Class Current: 514/27
• CPC Class Codes: A23K 10/37 from waste material from hydrolysates of wood or straw A23K10/32; from molasses A23K10/33
• CPC Class Codes: A23K 20/158 Fatty acids; Fats; Products containing oils or fats
• CPC Class Codes: A23K 50/20 for horses
• CPC Class Codes: A23L 33/105 Plant extracts, their artificial duplicates or their derivatives
• CPC Class Codes: A23V 2002/00 Food compositions, function of food ingredients or processes for food or foodstuffs
• CPC Class Codes: A23V 2200/33 High-energy foods and drinks, sports drinks
• CPC Class Codes: A23V 2250/21 Plant extracts
• CPC Class Codes: A23V 2250/2116 Flavonoids, isoflavones
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/353 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• CPC Class Codes: A61K 31/70 Carbohydrates; Sugars; Derivatives thereof sorbitol A61K31/047
• CPC Class Codes: A61K 31/7048 having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin , digitoxin or digoxin
• CPC Class Codes: A61K 36/752 Citrus, e.g. lime, orange or lemon
• CPC Class Codes: A61K 36/9068 Zingiber, e.g. garden ginger
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 1/14 Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: Y02P 60/87 Re-use of by-products of food processing for fodder production

Abstract

The present invention provides methods for decreasing post-exercise recovery time in a subject using compositions comprising one or more polymethoxylated flavones (PMFs). In preferred embodiments, the composition is an orange peel extract as described herein. In certain embodiments, post-exercise recovery time is the time for a subject'"'"'s post-exercise oxygen consumption (VO₂) level to return to a pre-exercise VO₂ level.

Claims

1. A method for decreasing post-exercise recovery time in a subject comprising administering to the subject an effective amount of a composition comprising a PMF fraction and a non-PMF fraction to decrease the time a subject requires to recover from exercising, wherein the PMF fraction comprises one or more PMFs, and wherein the composition is administered prior to exercising, during exercising, or within about 20 minutes after exercising by the subject.

2. The method of claim 1, wherein the decrease in post-exercise recovery time is between about 25 seconds to about 120 seconds.

3. The method of claim 1, wherein the post-exercise recovery time is the time taken for the subject'"'"'s post-exercise oxygen consumption (VO₂) level to return to a pre-exercise basal VO₂ level.

4. The method of claim 1, wherein the post-exercise recovery time is the time taken to complete the fast component of the return of the subject'"'"'s post-exercise oxygen consumption (VO₂) level towards a pre-exercise basal VO₂ level.

5. The method of claim 1 for decreasing the time for a subject who has ceased exercising to have their post-exercise oxygen consumption (VO₂) return to a pre-exercise basal VO₂ value comprising administering to the subject an effective amount of a composition comprising a PMF fraction and a non-PMF fraction wherein the PMF fraction comprises one or more PMFs and wherein the composition is orally administered to the subject prior to when the subject ceases exercising, whereby the time taken for the subject'"'"'s post-exercise VO₂ to return to a pre-exercise basal VO₂ value is shorter than the time for the subject'"'"'s post-exercise VO₂ to return to a pre-exercise basal VO₂ value when not administered with the composition.

6. The method of claim 1, wherein the one or more PMFs are selected from the group consisting of

5,6,7,3′

,4′

-pentamethoxyflavone(sinensetin);

5,6,7,8,3′

,4′

-hexamethoxyflavone(nobeletin);

5,6,7,8,4′

-pentamethoxyflavone(tangeretin);

5-hydroxy-6,7,8,3′

,4′

-pentamethoxyflavone(auranetin);

5-hydroxy-7,8,3′

,4′

-methoxyflavone;

5,7-dihydroxy-6,8,3′

,4′

-tetramethoxyflavone;

5,7,8,3′

,4′

-pentamethoxyflavone;

5,7,8,4′

-tetramethoxyflavone;

3,5,6,7,8,3′

,4′

-heptamethoxyflavone;

5-hydroxy-3,6,7,8,3′

,4′

-hexamethoxyflavone;

5-hydroxy-6,7,8,4′

-tetramethoxyflavone;

5,6,7,4′

-tetramethoxyflavone;

7-hydroxy-3,5,6,8,3′

,4′

-hexamethoxyflavone; and

7-hydroxy-3,5,6,3′

,4′

-pentamethoxyflavone.

7. The method of claim 6, wherein the PMF fraction of the composition consists essentially of

5,6,7,3′

,4′

-pentamethoxyflavone(sinensetin);

5,6,7,8,3′

,4′

-hexamethoxyflavone(nobeletin);

5,6,7,8,4′

-pentamethoxyflavone(tangeretin);

5-hydroxy-6,7,8,3′

,4′

-pentamethoxyflavone(auranetin);

5-hydroxy-7,8,3′

,4′

-methoxyflavone;

5,7-dihydroxy-6,8,3′

,4′

-tetramethoxyflavone;

5,7,8,3′

,4′

-pentamethoxyflavone;

5,7,8,4′

-tetramethoxyflavone;

3,5,6,7,8,3′

,4′

-heptamethoxyflavone;

5-hydroxy-3,6,7,8,3′

,4′

-hexamethoxyflavone;

5-hydroxy-6,7,8,4′

-tetramethoxyflavone;

5,6,7,4′

-tetramethoxyflavone;

7-hydroxy-3,5,6,8,3′

,4′

-hexamethoxyflavone;

or

7-hydroxy-3,5,6,3′

,4′

-pentamethoxyflavone.

8. The method of claim 1, wherein the PMF fraction consists of one or more PMF selected from the group consisting of

5,6,7,3′

,4′

-pentamethoxyflavone(sinensetin);

5,6,7,8,3′

,4′

-hexamethoxyflavone(nobeletin);

5,6,7,8,4′

-pentamethoxyflavone(tangeretin);

5-hydroxy-6,7,8,3′

,4′

-pentamethoxyflavone(auranetin);

5-hydroxy-7,8,3′

,4′

-methoxyflavone;

5,7-dihydroxy-6,8,3′

,4′

-tetramethoxyflavone;

5,7,8,3′

,4′

-pentamethoxyflavone;

5,7,8,4′

-tetramethoxyflavone;

3,5,6,7,8,3′

,4′

-heptamethoxyflavone;

5-hydroxy-3,6,7,8,3′

,4′

-hexamethoxyflavone;

5-hydroxy-6,7,8,4′

-tetramethoxyflavone;

5,6,7,4′

-tetramethoxyflavone;

7-hydroxy-3,5,6,8,3′

,4′

-hexamethoxyflavone; and

7-hydroxy-3,5,6,3′

,4′

-pentamethoxyflavone.

9. The method of any one of claim 1, wherein the one or more PMFs constitute an about 25% to about 75% w/w fraction of the composition.

10. The method of claim 9, wherein the composition is a food, food additive, dietary supplement, or medical food.

11. The claim 1, wherein the composition comprises a non-PMF fraction that comprises a physiologically acceptable carrier or excipient and a PMF fraction that comprises one or more PMFs selected from the group consisting of

5,6,7,3′

,4′

-pentamethoxyflavone(sinensetin);

5,6,7,8,3′

,4′

-hexamethoxyflavone(nobeletin);

5,6,7,8,4′

-pentamethoxyflavone(tangeretin);

5-hydroxy-6,7,8,3′

,4′

-pentamethoxyflavone(auranetin);

5-hydroxy-7,8,3′

,4′

-methoxyflavone;

5,7-dihydroxy-6,8,3′

,4′

-tetramethoxyflavone;

5,7,8,3′

,4′

-pentamethoxyflavone;

5,7,8,4′

-tetramethoxyflavone;

3,5,6,7,8,3′

,4′

-heptamethoxyflavone;

5-hydroxy-3,6,7,8,3′

,4′

-hexamethoxyflavone;

5-hydroxy-6,7,8,4′

-tetramethoxyflavone;

5,6,7,4′

-tetramethoxyflavone;

7-hydroxy-3,5,6,8,3′

,4′

-hexamethoxyflavone; and

7-hydroxy-3,5,6,3′

,4′

-pentamethoxyflavone.

12. The method of claim 1, wherein the composition comprises a non-PMF fraction that comprises a physiologically acceptable carrier or excipient and a PMF fraction that consists essentially of one or more PMFs selected from the group consisting of

5,6,7,3′

,4′

-pentamethoxyflavone(sinensetin);

5,6,7,8,3′

,4′

-hexamethoxyflavone(nobeletin);

5,6,7,8,4′

-pentamethoxyflavone(tangeretin);

5-hydroxy-6,7,8,3′

,4′

-pentamethoxyflavone(auranetin);

5-hydroxy-7,8,3′

,4′

-methoxyflavone;

5,7-dihydroxy-6,8,3′

,4′

-tetramethoxyflavone;

5,7,8,3′

,4′

-pentamethoxyflavone;

5,7,8,4′

-tetramethoxyflavone;

3,5,6,7,8,3′

,4′

-heptamethoxyflavone;

5-hydroxy-3,6,7,8,3′

,4′

-hexamethoxyflavone;

5-hydroxy-6,7,8,4′

-tetramethoxyflavone;

5,6,7,4′

-tetramethoxyflavone;

7-hydroxy-3,5,6,8,3′

,4′

-hexamethoxyflavone; and

7-hydroxy-3,5,6,3′

,4′

-pentamethoxyflavone.

13. The method of claim 1, wherein the composition comprises a non-PMF fraction that comprises a physiologically acceptable carrier or excipient and a PMF fraction that consists of one or more PMFs selected from the group consisting of

5,6,7,3′

,4′

-pentamethoxyflavone(sinensetin);

5,6,7,8,3′

,4′

-hexamethoxyflavone(nobeletin);

5,6,7,8,4′

-pentamethoxyflavone(tangeretin);

5-hydroxy-6,7,8,3′

,4′

-pentamethoxyflavone(auranetin);

5-hydroxy-7,8,3′

,4′

-methoxyflavone;

5,7-dihydroxy-6,8,3′

,4′

-tetramethoxyflavone;

5,7,8,3′

,4′

-pentamethoxyflavone;

5,7,8,4′

-tetramethoxyflavone;

3,5,6,7,8,3′

,4′

-heptamethoxyflavone;

5-hydroxy-3,6,7,8,3′

,4′

-hexamethoxyflavone;

5-hydroxy-6,7,8,4′

-tetramethoxyflavone;

5,6,7,4′

-tetramethoxyflavone;

7-hydroxy-3,5,6,8,3′

,4′

-hexamethoxyflavone; and

7-hydroxy-3,5,6,3′

,4′

-pentamethoxyflavone.

14. The method of claim 9, wherein the composition is orally administered to the subject.

15. The method of claim 14, wherein the composition is administered in a dry form.

16. The method of claim 14, wherein the composition is administered in a liquid form.

17. The method of claim 14, wherein the subject is a human.

18. The method of claim 14, wherein the subject is a horse.

19. The method of claim 14, wherein the subject is a dog.

20. The method of claim 17, wherein about 50 mg to about 1000 mg of the PMF fraction in the composition is administered to the subject.

21. The method of claim 1, wherein the non-PMF fraction comprises a bioactive ingredient.

22. The method of claim 21, wherein the bioactive ingredient is ginger extract.

23. The method of claim 1, wherein the composition is administered within about 2 hours, about 1 hour or within about 30 minutes before the subject exercises.

24. The method of claim 1, wherein the composition is administered while the subject exercises.

25. The method of claim 1, wherein the composition comprises molecules isolated from orange peels and from ginger.

26. A method for decreasing post-exercise recovery time in a subject comprising administering to the subject an effective amount of a composition comprising a ginger extract to decrease the time a subject requires to recover from exercising, wherein the composition is administered prior to exercising, during exercising, or within about 20 minutes after exercising by the subject.

27. The method of claim 26, wherein the ginger extract further comprises an orange peel extract.